NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) today announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (“Adcock Ingram”), a leading South African pharmaceutical and healthcare company. With the completion of this transaction, NATCO’s shareholding in Adcock Ingram has increased from 35.75% to 49%.
The acquisition was completed through NATCO Pharma South Africa Proprietary Limited, NATCO’s wholly owned subsidiary in South Africa. The transaction involved the purchase of shares for an aggregate consideration of approximately ZAR 1.81 billion, equivalent to around ₹1,060 crore at the applicable transaction exchange rate.
The completion of the additional stake acquisition represents a significant milestone in NATCO’s long-term growth strategy in the African pharmaceutical market. The increased ownership in Adcock Ingram reinforces NATCO’s commitment to expanding its global footprint and creating greater strategic opportunities in the healthcare sector.
NATCO initially acquired a 35.75% stake in Adcock Ingram through its participation in the company’s delisting process in 2025. The transaction followed the announcement of a firm intention offer in July 2025, shareholder approval in October 2025, and completion of the acquisition in November 2025. Subsequently, NATCO’s Board approved the acquisition of an additional 13.25% stake in July 2026, and the transaction has now been completed after fulfilling customary closing conditions and regulatory requirements.
The enhanced stakeholding provides NATCO with a stronger position in one of Africa’s established pharmaceutical markets and supports its broader vision of building sustainable international partnerships. Adcock Ingram’s strong market presence, healthcare capabilities, and regional expertise complement NATCO’s focus on innovation, specialty medicines, and high-value therapeutic areas.
NATCO Pharma Limited is a publicly listed pharmaceutical company on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of approximately US$1.82 billion. Established in 1981, the company is recognised for its pharmaceutical research and development capabilities and its focus on developing niche, high-potential medicines.
NATCO has built a strong presence in areas including oncology, cardiology, neurology, and other specialised therapeutic segments. The company manufactures products across nine state-of-the-art facilities that are certified and approved by leading global regulatory authorities, including the US Food and Drug Administration (US FDA), Brazil’s ANVISA, Health Canada, and the World Health Organization.
With a growing global presence, NATCO exports its pharmaceutical products to more than 50 countries, including the United States, Brazil, and Canada. The increased investment in Adcock Ingram marks another step in NATCO’s continued efforts to expand access to quality healthcare solutions worldwide.
